{
    "nctId": "NCT05033925",
    "briefTitle": "Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients",
    "officialTitle": "Safety and Clinical Efficacy Evaluation of Awar-awar Leaves (Ficus Septica Burm. F.) Active Fraction Capsule as Chemotherapy Complement in Stage IV Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Stage IV",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 324,
    "primaryOutcomeMeasure": "Quality of life assessment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, at least 18 years old\n* Welfare scale 0, 1, and 2 (ECOG - WHO)\n* Patients with stage IV breast cancer who have histopathological data according to the TNM Classification of Malignant Tumors (TNM) from American Joint Committee on Cancer (AJCC) 8th edition 2017\n* Patients who are willing to participate in the test and sign an informed consent\n* Patients who undergo breast cancer chemotherapy with luminal B sub-type or triple negative with anthracycline base\n* Patients who are willing and able to fill out a questionnaire\n* The patients who are willing and able to comply with the test protocols during the test\n\nExclusion Criteria:\n\n* Unable to meet the test protocol\n* Patients with liver and kidney disorders\n* Patients with other diseases/disorders that are meaningful according to the investigators will be excluded from the test\n* Patients with cancer that has metastasized to the brain\n* Pregnant women and breastfeeding mothers\n* Patients with the ejection fraction smaller-than or equal to 55%",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}